Last reviewed · How we verify

PATH — Portfolio Competitive Intelligence Brief

PATH pipeline: 11 marketed, 0 filed, 4 Phase 3, 10 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

11 marketed 0 filed 4 Phase 3 10 Phase 2 15 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Meningococcal A conjugate vaccine Meningococcal A conjugate vaccine marketed Conjugate vaccine Neisseria meningitidis serogroup A polysaccharide capsule Immunology / Infectious Disease
Seasonal trivalent inactivated influenza vaccine Seasonal trivalent inactivated influenza vaccine marketed Inactivated viral vaccine Immunology
yellow fever vaccine (YFV) yellow fever vaccine (YFV) marketed Live attenuated vaccine Immunology / Infectious Disease
Vaccine produced in new facility Vaccine produced in new facility marketed vaccine Immunology
Vaccine produced in existing facility Vaccine produced in existing facility marketed
Human Rotavirus Vaccine Human Rotavirus Vaccine marketed
Live, attenuated measles vaccine Live, attenuated measles vaccine marketed
Measles, mumps, rubella vaccine Measles, mumps, rubella vaccine marketed Live attenuated vaccine Immunology / Infectious Disease
Measles Vaccine (MV) Measles Vaccine (MV) marketed Live attenuated vaccine Immunology / Infectious Disease
Rotavirus vaccine Rotavirus vaccine marketed Live attenuated vaccine Immunology / Infectious Disease
Reactive Focal Drug Administration Reactive Focal Drug Administration marketed Oncology
TV P2-VP8 TV P2-VP8 phase 3 Vaccine

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Merck Sharp & Dohme LLC · 5 shared drug classes
  2. GlaxoSmithKline · 5 shared drug classes
  3. Sanofi Pasteur, a Sanofi Company · 5 shared drug classes
  4. PT Bio Farma · 4 shared drug classes
  5. Centers for Disease Control and Prevention · 4 shared drug classes
  6. Jiangsu Province Centers for Disease Control and Prevention · 4 shared drug classes
  7. Institute of Medical Biology, Chinese Academy of Medical Sciences · 4 shared drug classes
  8. Novartis · 4 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for PATH:

Cite this brief

Drug Landscape (2026). PATH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/path. Accessed 2026-05-13.

Related